Studying Biomarkers in Patients With Pancreatic Cancer

CompletedOBSERVATIONAL
Enrollment

53

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Pancreatic Cancer
Interventions
GENETIC

protein analysis

Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.

OTHER

laboratory biomarker analysis

A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.

Trial Locations (3)

37064

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville

Vanderbilt-Ingram Cancer Center at Franklin, Nashville

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00900003 - Studying Biomarkers in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter